Content: In this interactive breakfast session invited international speaker, Professor Melinda Irwin from Yale School of Public Health, will discuss current and future opportunities and challenges in physical activity and cancer research and clinical care. Prof Irwin is a prominent leader in the field of physical activity and cancer risk and mortality. Her research over the past 15 years has focused on randomized trials of exercise and weight loss on biological markers, treatment side effects and quality of life in cancer patients and survivors.
Speaker: Melinda Irwin
Content: This breakfast symposium will provide attendees with insights into breakthrough cancer pain: the definition of breakthrough cancer pain, how its management is evolving and what this means for the doctor, the palliative care team and the patient. Professor Richard Chye, Palliative Care specialist at St Vincent’s Hospital, Sydney, will share his knowledge relating to the management of breakthrough cancer pain. A patient will also discuss the impact of effective breakthrough cancer pain management on his quality of life. There will be time for questions and discussion.
Speaker: Professor Ricahrd Chye Director, Sacred Heart Supportive & Palliative Care St Vincent’s Hospital Sydney, NSW
This breakfast symposium will give attendees insights into the practical aspects of proactively managing everolimus-induced stomatitis In the recently reported SWISH clinical trial, prophylactic use of a dexamethasone solution as a mouthwash four times daily for the first 8 weeks of treatment significantly reduced the incidence of everolimus-induced stomatitis1. In the light of the SWISH trial outcome, this session will discuss the practicalities of managing everolimus-associated stomatitis in Australia with two real-world perspectives. Dr Lina Pugliano will review the SWISH trial data and then discuss her experiences and give her insights into prophylactically managing everolimus-related stomatitis. Pharmacist Obaid Fazli will outline different approaches to supplying everolimus patients with steroidal mouthwash that are currently being practised in Australia, highlighting the practical benefits and limits of these.
1Rugo, HS, J Clin Oncol 34, 2016 (suppl; abstr 525)
Dr Lina Pugliano, Medical Oncologist Northern Cancer Institute (NCI) St Leonards, Sydney, NSW
SWISH trial recap: using prophylactic steroidal mouthwash to control everolimus-associated stomatitis
Obaid Fazli, Assistant Deputy Director and Senior Oncology Pharmacist, Monash Health-Moorabbin Pharmacy Department, Melbourne, Victoria
Putting SWISH into practice: adapting SWISH to the Australian setting
Welcome by COSA President
Welcome to Country by local Indigenous group
Official opening by His Excellency the Honorable Paul de Jersey AC, Governor of Queensland
5:20 PM Panel Discussion
Speaker: Dr Tim Grice
"Are all opioids created equal?… Join us to learn more about Palexia and its role in the treatment of Chronic Cancer Pain"